We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AAM: Tariffs on Chinese Generics and Biosimilars Would Hurt the U.S.

AAM: Tariffs on Chinese Generics and Biosimilars Would Hurt the U.S.

MoneyinAir.gif
June 27, 2019

Chinese generics and biosimilars should be allowed to flow into the U.S. without punitive tariffs, the generics makers’ largest trade association has said.

In a letter to  U.S. Trade Representative Robert Lighthizer, the Association for Accessible Medicines says that the Trump administration should stay the course and continue to exempt Chinese drugs and active pharmaceutical ingredients from the tariffs list. The administration has imposed tariffs of up to 25 percent on an array of goods and materials, but it would cause “disproportionate economic harm” if imported generics were hit with the duties, the association says.

AAM submitted the letter “because we wanted to support the Trump Administration’s decision, as described in the Federal Register, to exempt pharmaceuticals and pharmaceutical inputs, while also emphasizing why such a decision was important for the U.S. health care system, “ says Jonathan Kimball, the group’s vice president of trade and international affairs.

The letter cites unnamed analysts who believe that drug tariffs would likely hit generic drugmakers harder than name brand manufacturers, as generic drug production incurs higher manufacturing costs relative to their price.

View today's stories

Pharmaceuticals Regulatory Affairs

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

  • FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing